These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 31729042)

  • 1. Risk of RBC alloimmunization in multiple myeloma patients treated by Daratumumab.
    Ye Z; Wolf LA; Mettman D; Plapp FV
    Vox Sang; 2020 Feb; 115(2):207-212. PubMed ID: 31729042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing transfusion management of multiple myeloma patients receiving daratumumab-based regimens.
    Phou S; Costello C; Kopko PM; Allen ES
    Transfusion; 2021 Jul; 61(7):2054-2063. PubMed ID: 33960433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody incidence and red blood cell transfusions in patients on daratumumab.
    Tauscher C; Moldenhauer S; Bryant S; DiGuardo M; Jacob EK
    Transfusion; 2021 Dec; 61(12):3468-3472. PubMed ID: 34617617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of an in-house trypsin-based method to resolve the interference of daratumumab.
    Ibeh N; Baine I; Rudon LF; Lomas-Francis C; Jhang JS; Galdon P; Westhoff CM; Velliquette RW; Arinsburg SA
    Transfusion; 2021 Oct; 61(10):3000-3007. PubMed ID: 34472116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extending shelf life of dithiothreitol-treated panel RBCs to 28 days.
    Sigle JP; Mihm B; Suna R; Bargetzi M
    Vox Sang; 2018 May; 113(4):397-399. PubMed ID: 29512161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resolving the daratumumab interference with blood compatibility testing.
    Chapuy CI; Nicholson RT; Aguad MD; Chapuy B; Laubach JP; Richardson PG; Doshi P; Kaufman RM
    Transfusion; 2015 Jun; 55(6 Pt 2):1545-54. PubMed ID: 25764134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Challenges of Daratumumab in Transfusion Medicine.
    Dizon MF
    Lab Med; 2017 Feb; 48(1):6-9. PubMed ID: 27794527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions.
    Aygun B; Padmanabhan S; Paley C; Chandrasekaran V
    Transfusion; 2002 Jan; 42(1):37-43. PubMed ID: 11896310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of Daratumumab on transfusion service costs.
    Cushing MM; DeSimone RA; Goel R; Hsu YS; Parra P; Racine-Brzostek SE; Degtyaryova D; Lo DT; Morrison M; Crowley KM; Rossi A; Vasovic LV
    Transfusion; 2019 Apr; 59(4):1252-1258. PubMed ID: 30620407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood component administration to multiple myeloma patients treated with daratumumab: suggesting a novel approach with use of 0.1 M dithiothreitol.
    Pandey P; Setya D; Kaul E; Ranjan S; Singh MK; Shankar A
    Immunohematology; 2020 Dec; 36(4):157-165. PubMed ID: 33544622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma.
    Chari A; Arinsburg S; Jagannath S; Satta T; Treadwell I; Catamero D; Morgan G; Feng H; Uhlar C; Khan I; Doshi P; Usmani S
    Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):44-51. PubMed ID: 29054515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct effects of daratumumab on indirect and direct antiglobulin tests: a new method employing 0.01 mol/L dithiothreitol for negating the daratumumab interference with preserving K antigenicity (Osaka method).
    Hosokawa M; Kashiwagi H; Nakayama K; Sakuragi M; Nakao M; Morikawa T; Kiyokawa T; Aochi H; Nagamine K; Shibayama H; Tomiyama Y
    Transfusion; 2018 Dec; 58(12):3003-3013. PubMed ID: 30267414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for new red blood cell alloantibodies after transfusion in patients with sickle cell disease.
    Rankin A; Darbari D; Campbell A; Webb J; Mo YD; Jacquot C; Delaney M; Luban NLC; Nickel RS
    Transfusion; 2021 Aug; 61(8):2255-2264. PubMed ID: 34002408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of clinical application of anti-CD38 and anti-CD47 monoclonal antibodies on blood group detection and transfusion therapy and treatment.
    Du C; Sui W; Huang H; Zhang Y; Ding X; Gao C; Wang Y
    Leuk Res; 2022 Nov; 122():106953. PubMed ID: 36182722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of new alloimmunization in patients on anti-CD38 treatment using tube LISS-IAT method.
    Safić Stanić H; Kruhonja Galić Z; Lukić M; Bingulac-Popović J; Jukić I
    Transfus Apher Sci; 2024 Apr; 63(2):103873. PubMed ID: 38267327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A blockage monoclonal antibody protocol as an alternative strategy to avoid anti-CD38 interference in immunohematological testing.
    Chinoca Ziza KN; Paiva TA; Mota SR; Dezan MR; Schmidt LC; Brunetta DM; Ricci G; Basques FV; Barroso-Duarte F; Rocha V; Mendrone-Junior A; Dinardo CL
    Transfusion; 2019 May; 59(5):1827-1835. PubMed ID: 30779172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of alloimmunization in sickle cell disease.
    Hudson KE; Fasano RM; Karafin MS; Hendrickson JE; Francis RO
    Curr Opin Hematol; 2019 Nov; 26(6):434-441. PubMed ID: 31483335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Red blood cell alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease.
    Balbuena-Merle R; Hendrickson JE
    Transfus Clin Biol; 2019 May; 26(2):112-115. PubMed ID: 30857806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Red blood cell alloimmunization and minor red blood cell antigen phenotypes in transfused Ghanaian patients with sickle cell disease.
    Boateng LA; Campbell AD; Davenport RD; Osei-Akoto A; Hugan S; Asamoah A; Schonewille H
    Transfusion; 2019 Jun; 59(6):2016-2022. PubMed ID: 30758856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.
    Quach H; Benson S; Haysom H; Wilkes AM; Zacher N; Cole-Sinclair M; Miles Prince H; Mollee P; Spencer A; Joy Ho P; Harrison SJ; Lee C; Augustson B; Daly J
    Intern Med J; 2018 Feb; 48(2):210-220. PubMed ID: 29415351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.